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MEETING SUMMARY
This educational symposium, sponsored by Britannia Pharmaceuticals Limited, was held during the 1st 
Congress of the European Academy of Neurology (EAN), which took place from 20th-23rd June 2015 in 
Berlin, Germany. The symposium reviewed the role of non-oral drug delivery strategies in patients with 
Parkinson’s disease (PD) and how they can overcome problems that occur with the gastrointestinal (GI) 
route of administration in many patients. GI dysfunction is recognised as a common problem in PD and 
may in fact be a preclinical marker of the disease. It can affect the absorption of oral medication 
resulting in OFF periods and unreliable control of motor symptoms, which in turn can have a negative 
impact on quality of life (QoL). Delayed time-to-ON (TTO) after an oral levodopa dose and dose 
failures are known to be significant contributors to total OFF time. Results of the recently completed 
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Gastrointestinal Dysfunction in 
Parkinson’s Disease
Professor Werner Poewe
Prof Poewe reminded delegates that while PD 
is traditionally considered to be primarily a 
movement disorder, it is in fact a multi-system 
disease and affects areas of the brain that are not 
directly involved in motor control, for example the 
hypothalamus, locus coeruleus, and raphe nuclei 
of the brainstem.1-3 PD pathology also extends into 
the peripheral autonomic nervous system involving 
sympathetic ganglia, cardiac sympathetic efferents, 
and the enteric nervous system (ENS).
The PRIAMO study4 was a multicentre survey 
that interviewed 1,072 consecutive PD patients 
at different stages of disease (treatment-naïve, 
stable, and complex) over a period of 12 months at 
55 centres in Italy to assess the prevalence of non- 
motor symptoms (NMS) in PD and their impact on 
QoL. The results found that 98.6% of patients with 
PD reported the presence of NMS. They occurred 
across all disease stages and many patients 
experienced multiple symptoms – the mean number 
of NMS per patient in the survey was 7.8. Notably, 
GI symptoms were present in 45% of newly 
diagnosed, untreated patients, 60% of those with 
stable disease, and 72% of those with complex 
disease (Figure 1).
Prof Poewe commented that, in many cases, if 
patients were not specifically asked about 
these symptoms, they might be overlooked. He 
highlighted the results of a study of 89 PD patients 
who undertook a validated NMS questionnaire 
(NMSQ), which was compared with standard 
neurology clinic reporting in case notes.5 Results of 
NMSQ found a mean of 11 different NMS per patient. 
In contrast, chart review showed a mean of 4.8 
NMS per patient, suggesting that some symptoms 
remain under-reported by patients unless 
questioned. In this study, constipation was reported 
by 48%, highlighting that GI problems are a 
frequent non-motor issue in PD.
AM-IMPAKT trial in patients with morning akinesia due to a delay in the onset of oral levodopa effect 
demonstrate that apomorphine intermittent injection (penject) is able to provide rapid and effective 
resolution of such complications, restoring patients to the ON state quickly and allowing them to get on 
with their daily activities.
Figure 1: Prevalence of non-motor Parkinson’s disease symptoms in patients with treatment-naïve, 
stable, and complex disease: results of the PRIAMO study.4 
Reproduced with permission of Movement Disorders.
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GI dysfunction in PD patients is now known to 
occur at all levels of the GI tract.6,7 Common clinical 
features include sialorrhoea (drooling), dysphagia, 
gastroparesis, colonic dysmotility (constipation), 
and anorectal dysfunction. These symptoms have 
a range of clinical consequences for patients, and 
in some cases can be a burden for their caregivers 
too, resulting in social embarrassment, reduced 
appetite, weight loss, aspiration of food, and impact 
on effective absorption of oral PD medication. 
It is now recognised that development of NMS 
can precede the onset of motor symptoms in PD. 
A recent study was undertaken to investigate the 
timing of onset of NMS in PD and the possible 
association with motor phenotype using a custom-
made questionnaire in 109 newly diagnosed, 
untreated PD patients and 107 age and sex-
matched healthy controls from 11 centres in Spain 
and Austria.8 Seventeen of 31 different NMS were 
found to be more common in PD patients than in 
controls (p<0.05). Notably, in >50% of PD patients, 
NMS preceded the onset of motor symptoms. 
The symptoms reported more frequently in the 
2-10-year premotor period were smell loss, mood 
disturbances, taste loss, excessive sweating, fatigue, 
and pain. Constipation, dream-enacting behaviour, 
excessive daytime sleepiness, and postprandial 
fullness were frequently perceived more than 
10 years before motor symptoms occurred. 
The natural history of PD is characterised by a 
gradual decline in striatal dopamine through 
the preclinical and prodromal stages, eventually 
reaching an 80% deficit which is indicative of 
a diagnosis of PD and represents a 50% loss of 
neurons in the substantia nigra. The identification 
and characterisation of prodromal NMS of PD is 
the subject of considerable research. In the case of 
GI dysfunction, studies by Abbott and colleagues9 
found that constipation and infrequent bowel 
movements were associated with a significantly 
elevated risk of future PD (p=0.005). Further 
studies by this group found evidence that 
constipation can predate the extrapyramidal signs 
of PD and could be one of the earliest markers of 
the beginning of the PD process. The preclinical 
phase of PD is often characterised by the presence 
of incidental Lewy bodies (ILB). Assessment of 
bowel movement frequency in 245 men, aged 
71-93 years without clinical evidence of PD who later 
received post-mortem examinations, found that 
the percentage of brains with ILB declined with 
increasing bowel movement frequency (p=0.013).10 
There is a substantial need for an accurate early 
diagnostic test for PD, and with this in mind, 
researchers have been focussing on the potential 
link between ENS pathology and preclinical or 
prodromal PD. Alpha-synuclein is the primary 
structural component of Lewy bodies and its 
aggregation is thought to play a critical role in the 
Figure 2: Levodopa dose is predictive of the development of dyskinesia and wearing-off: results of the 
STRIDE-PD study.17
*Rates at study termination. 
Reproduced with permission of Movement Disorders.
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development of PD. Alpha-synuclein pathology 
has been found in body tissues outside of the brain 
not usually associated with PD. A recent study has 
suggested that alpha-synuclein may be present in 
colonic biopsy tissue in early or even prodromal 
PD before the development of characteristic PD 
motor symptoms, and may therefore be a potential 
diagnostic biomarker for pre-motor PD.11 Archival 
colon biopsy samples obtained 2-5 years before 
PD onset were analysed for three patients with 
PD. All patients showed immunostaining for alpha-
synuclein at least 2 years before the first motor PD 
symptom occurred. In contrast, no corresponding 
alpha-synuclein immunostaining was seen in 
23 healthy controls. 
Prof Poewe concluded by highlighting that many 
aspects of GI dysfunction in PD are now recognised 
to have a significant potential impact on oral drug 
delivery and hence clinical efficacy.12 Difficulties 
in swallowing can lead to adherence problems in 
patients receiving oral medication. Delayed gastric 
emptying (gastroparesis) can lead to a reduction 
in the speed of oral levodopa delivery to its site 
of absorption in the small intestine, resulting in a 
‘delayed ON’ or even dose failure. Competition 
between levodopa and proteins for transport 
across the GI mucosa can result in unpredictable 
drug responses. The OFF periods that the 
patient experiences will result in motor and non-
motor fluctuations that have a negative impact 
on their QoL, and so Prof Poewe considered 
that it was important that alternative therapeutic 
interventions were sought in such cases. 
Wearing OFF and Delayed ON – Motor 
and Non-Motor Fluctuations
Professor Fabrizio Stocchi
Prof Stocchi described how ‘ON–OFF’ fluctuations 
in PD patients receiving chronic oral levodopa 
therapy were first described by Marsden and Parkes 
in 1976.13 Motor complications include both motor 
fluctuations and dyskinesias. Motor fluctuations 
can include predictable end-of-dose ‘wearing-
off’ phenomena, peripheral problems such as 
delayed ON (for example morning akinesia) or 
‘no ON’ (dose failure), and unpredictable ON–OFF 
periods. Dyskinesias may be peak-dose effects, 
distressing and painful diphasic dyskinesias, or 
painful OFF-period dystonia. He highlighted how 
debilitating and distressing these different motor 
complications can be in the real-life setting with a 
series of patient videos. In addition to classical motor 
fluctuations, many PD patients also experience 
non-motor fluctuations, such as anxiety, panic 
attacks, pain, fatigue, mood changes, urinary 
urgency, and swallowing difficulties.14
Wearing-off is commonly associated with the 
later stages of PD. However, a review of preclinical 
and clinical data suggest that fluctuations in the 
response to levodopa may appear much earlier than 
previously thought, and can be present in patients 
with early disease.15 Prof Stocchi presented the 
results of the DEEP study (Early DEtection of 
wEaring off in Parkinson disease),16 which was 
undertaken to assess the frequency of wearing-off  
in PD patients and its impact on QoL using a 
validated screening tool, WOQ-19. These results 
showed that the frequency of wearing-off  
increased with duration of disease such that, after 
10 years, around 80% of PD patients experienced 
wearing-off phenomena.
Prof Stocchi went on to highlight some of the risk 
factors underlying complications in PD. He reviewed 
a secondary analysis of the STalevo Reduction 
In Dyskinesia Evaluation in Parkinson’s Disease 
(STRIDE-PD) study that had investigated the effect 
of levodopa dose and other risk factors on the 
development of dyskinesias and wearing-off. The 
results demonstrated that time to development 
of dyskinesias and time to wearing-off both 
correlated with the dose of oral levodopa 
(Figure 2).17 Multivariate analyses showed that 
factors predictive of dyskinesia included young age 
at onset, higher levodopa dose, low body weight, 
female gender, and more severe Unified Parkinson’s 
Disease Rating Scale (UPDRS) Part III scores. 
Predictors of wearing-off included higher baseline 
UPDRS scores, higher levodopa dose, and the 
female gender.
Motor complications in PD patients are recognised 
to have a significant impact on QoL.18 This was 
investigated in 143 patients with PD who were 
evaluated using the Hoehn and Yahr scale and the 
motor part of the UPDRS. In addition, a specific 
PD QoL questionnaire (39-item version, PDQ-39) 
was used. Motor complications, including early 
morning akinesia, nocturnal akinesia, end-of-dose 
fluctuations, paradoxical fluctuations, and 
unpredictable OFFs, were found to significantly 
worsen the PDQ-39 Summary Index of patients 
with PD. The dimensions of mobility, activities of 
daily living, stigma, and communication were most 
strongly affected. 
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Prof Stocchi described an ongoing study, the Time 
to ON Questionnaire in PD (TOQ-PD), which is a 
survey being undertaken in PD patients attending 
a routine clinical appointment to help characterise 
their early morning OFF problems (unpublished 
data). This pilot study is a non-interventional, 
outpatient study being conducted in 90 consecutive 
patients treated in movement disorders centres. 
As part of the inclusion criteria, patients, in the 
opinion of the prescribing physician, had to be able 
to understand and describe the changes in ON and 
OFF clinical status. A total of 25% of patients felt 
that their medication was taking >1 hour to work. 
Almost 52% of patients found it troublesome 
when their first daily dose of levodopa took longer 
than usual to work (delayed ON), did not work 
well (suboptimal ON), or did not work at all (dose 
failure). In the case of the mealtime dose of 
levodopa, this figure was 56%. Patients also 
described a range of problematic symptoms that 
occurred while waiting for their levodopa to work, 
including slowness, stiffness, and difficulty walking.
Prof Stocchi also recognised the contribution 
of peripheral factors to delayed ON and dose 
failure with oral levodopa, for example swallowing 
difficulties which he clearly illustrated with a series 
of endoscopic videos. Swallowing abnormalities 
in PD patients include abnormal lingual control of 
swallowing, lingual festination, delayed swallowing 
reflex (a tendency of parkinsonian patients to 
swallow during the inspiration phase increasing 
the possibility of aspiration), and repetitive or 
involuntary reflux from the vallecula and piriform 
sinuses into the oral cavity. These troublesome 
symptoms need careful management and 
might require a change in the type of food and 
diet consumed. Dopaminergic drugs may 
improve swallowing; however, alternative routes 
of administration such as transdermal therapy, 
subcutaneous infusion, or intraduodenal infusion 
should be considered. 
Gastroparesis, or delayed gastric emptying, is 
common in PD, resulting in postprandial fullness, 
nausea, vomiting, and impaired drug absorption 
that in turn leads to delayed ON or no ON.19 
Recently, delayed TTO and dose failures have been 
recognised as a significant proportion of total OFF 
time, comprising more than twice the duration of 
wearing-off in PD patients.20 This was illustrated 
clearly in a pharmacokinetic study of levodopa 
given every 4 hours undertaken by Prof Stocchi, 
which revealed a substantial proportion of OFF 
time over the day, and particularly delayed ON 
(unpublished data).
In view of the high prevalence of GI dysfunction in 
PD patients and its impact on the efficacy of oral 
medication, a range of alternative PD medication 
formulations and routes of administration have 
been investigated in this setting with varying 
degrees of success. These include liquid levodopa, 
transdermal dopamine agonists, subcutaneous 
apomorphine, and intraduodenal levodopa infusion. 
Prof Stocchi also reviewed the strategies that 
had been investigated to tackle the phenomenon 
of wearing-off.21 Standard oral formulations of 
levodopa result in pulsatile dopaminergic 
stimulation and are not able to maintain steady 
plasma levels throughout the day. Therefore, 
continuous dopaminergic stimulation (CDS) has 
been proposed to more closely mimic the 
physiological situation and help overcome the 
motor complications that occur with standard 
oral therapy.22-25 Other options include modifying 
the timing or formulation of levodopa, modifying 
the actions of levodopa by using catechol-O-
methyltransferase (COMT) inhibitors (entacapone, 
tolcapone), the use of longer-acting dopamine 
agonists (such as pramipexole, ropinirole, rotigotine, 
apomorphine, or pergolide), or by modifying 
the actions of dopamine at the synaptic level 
by using a monoamine oxidase B (MAO-B) 
inhibitor (rasagiline). 
One option for CDS that is backed by considerable 
clinical experience is continuous apomorphine 
infusion: it has proven efficacy for PD patients 
with motor fluctuations that are uncontrolled by 
conventional oral or transdermal medication and 
is well tolerated. In a recent review, the data for 
390 patients from 21 open-label uncontrolled 
studies were pooled.26 The results showed a 58.2% 
average OFF time reduction (range 38-80%) and 
a levodopa-sparing effect with a 45.9% reduction 
in levodopa-equivalent dose during an observation 
period of 24.8 months (6-57 months). In the case 
of dyskinesias, 6 of 11 long-term studies showed 
~50% reduction in duration and ~45% reduction 
in severity of dyskinesias with continuous 
apomorphine infusion.27 Biphasic and peak-dose 
dyskinesias showed the best response to therapy. 
A study by Prof Stocchi’s own research group 
showed a significant and sustained reduction in 
the severity of dyskinesias with long-term use of 
continuous apomorphine infusion over a period 
of 5 years.28 
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As with all therapeutic interventions, Prof Stocchi 
noted that it was important to select the right 
patient in order to maximise the success 
of treatment. He advised that continuous 
apomorphine infusion should be considered in all 
PD patients who develop features of complicated 
disease irrespective of their age or disease duration. 
This should include patients who have become 
progressively disabled, those who experience 
increasing or long OFF periods, those who have 
moderate-to-severe dyskinesias, and those who 
are already suffering with motor complications or 
who have developed levodopa-induced dyskinesias. 
PD patients who might not be suitable for this 
treatment option include those with a poor 
response to levodopa; those with severe cognitive 
impairment; patients with contraindications such 
as hepatic insufficiency, pregnancy, or lactation; 
patients without support to help them manage 
the infusion device; and those with excessive 
skin problems. 
Prof Stocchi concluded his presentation by 
noting that continuous apomorphine infusion has 
several advantages over other CDS options for PD 
patients who experience motor fluctuations despite 
optimised oral medication. Importantly, it is the 
least invasive of the three advanced therapies 
(apomorphine infusion, intrajejunal levodopa 
infusion, and deep brain stimulation) and is 
completely reversible. Apomorphine infusion is 
practical to use – it can be initiated during inpatient 
hospitalisation or in a day-hospital setting – and 
does not induce tolerance.28
Apomorphine Penject – AM-IMPAKT 
Trial Results and Best Clinical Practice
Professor Stuart Isaacson
Prof Isaacson noted that over the past two 
decades the issue of motor fluctuations and OFF 
periods in PD patients had focussed very much on 
end-of-dose wearing-off of oral PD medication. 
However, it is now becoming increasingly 
recognised that in addition to end-of-dose wearing 
off there are many other contributors to total OFF 
time, including nocturnal akinesia, morning akinesia, 
postprandial akinesia, delayed TTO, and dose failure 
(no ON). Studies have now shown that delayed 
TTO is in fact a major contributor to OFF time, 
being more than twice the duration of wearing-
off.20 He acknowledged that when oral levodopa 
is first used to treat PD patients, the clinical effect 
of each levodopa dose is rapid, reliable, and 
sustained with an onset of around 20 mins and a 
long-duration response. However, with chronic 
treatment, the long-duration response is replaced 
by a short-duration response and OFF periods, 
such as wearing-off and delayed TTO, become 
more frequent.
Levodopa has been the recognised ‘gold standard’ 
treatment for PD for the past 50 years but it is 
an oral treatment that must be swallowed and 
therefore its efficacy may be affected if the 
patient also suffers from GI tract dysfunction. The 
GI tract is known to be dysfunctional in many PD 
patients and this can occur almost a decade or 
more before PD is clinically diagnosed. In addition, 
medications used to treat PD may also contribute 
to GI dysfunction, including levodopa, dopamine 
agonists, anticholinergics, amantadine, and 
inhibitors of MAO-B and COMT. GI symptoms, such 
as gastroparesis, can impact on the effectiveness 
of oral levodopa by delaying its delivery to, and 
absorption in, the small intestine,19,29 resulting in 
delayed ON or even dose failure.30 Absorption of 
levodopa can be affected by competition with 
ingested protein for the amino acid transporter. 
In addition, recent studies have confirmed a high 
prevalence of small intestinal bacterial overgrowth 
in PD, which may also affect levodopa absorption, 
and have reported an association with poor motor 
function, longer daily OFF time, and more episodes 
of delayed ON and no ON.31,32
An investigation of the prevalence of delayed 
gastric emptying of solids in PD was undertaken 
in 22 healthy subjects and 36 patients at different 
clinical stages of PD using a 13C-sodium octanoate 
breath test (OBT).29 The OBT was able to detect 
a significant delay in gastric emptying of a solid 
test meal in patients with PD that was associated 
with disease severity, illustrating how common 
gastroparesis is across all disease stages. While 
liquids are able to empty from the stomach quicker 
than solids, in PD patients there may still be a delay 
in gastric emptying. In the case of oral levodopa, 
Doi and colleagues19 demonstrated a significant 
relationship between levodopa pharmacokinetics 
and gastric emptying in PD patients, suggesting 
that delayed gastric emptying is a causative factor 
for producing the delayed ON.
The high prevalence of early morning OFF (EMO) 
periods has been demonstrated in the results of 
the international, multicentre EUROPAR study.33 
EMO periods occur when the first morning dose 
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of oral levodopa has a delayed onset of action and 
were found in this study to be present in 59.7% of 
the 320 patients, occurring throughout the course 
of PD in mild, moderate, and severe disease. Prof 
Isaacson highlighted that EMO periods are often an 
early sign of emerging motor fluctuations and the 
loss of the long-duration levodopa response, and 
can occur despite attempts to optimise oral 
therapy and the use of multiple medications. 
During episodes of morning akinesia the patient 
can experience impaired mobility and function until 
the oral levodopa takes effect, and this is known to 
have a negative effect on patient QoL.18 Although 
morning akinesia represents the motor component 
of EMO periods, both motor and NMS are frequent 
in PD patients at these times.
A range of treatment strategies have been 
employed in an attempt to resolve the issue of 
morning akinesia, for example the use of long- 
acting dopamine agonists or MAO-B inhibitors, or 
by aiming to improve delivery of levodopa to the 
proximal small intestine by using liquid, dispersible, 
modified, or higher-dose levodopa. However, none 
of these approaches addressed the problem of PD 
patients who have gastroparesis where emptying 
of both solids and liquids may be impaired,29 and 
in whom a delayed onset of levodopa effect may 
still occur. This has been illustrated in a study 
by Chaná and colleagues,30 who assessed the 
pharmacokinetics of levodopa in 19 patients with 
advanced PD with and without a delayed onset 
of first levodopa dose in the morning. The 
results confirmed that the difference in plasma 
concentrations of levodopa between the two 
groups was most likely due to delayed gastric 
emptying, and this phenomenon probably underlies 
the delayed clinical response to oral levodopa in 
many PD patients.30
Figure 3: Apomorphine pen injection. 
Figure 4:  Change from baseline in time-to-ON following apomorphine injection: results of AM-IMPAKT 
[unpublished data].
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These problems highlight the need to consider 
non-oral therapies to manage motor symptoms 
in this setting. The potent dopamine agonist 
apomorphine administered subcutaneously has 
provided clinicians with an effective option for the 
rapid resolution of the parkinsonian symptoms 
for over 25 years. Prof Isaacson considered that 
subcutaneous apomorphine intermittent injection 
offered an easy and practical therapeutic option 
for managing EMO as it avoided the oral route of 
administration that could be affected by delayed 
gastric emptying or impaired intestinal absorption. 
The clinical efficacy of apomorphine infusion 
has been confirmed in a range of randomised, 
controlled clinical trials undertaken in the USA. In 
the APO202 study of 29 PD patients with motor 
fluctuations and prolonged OFF time despite 
aggressive oral therapy, apomorphine injection 
was able to reverse 95% of OFF episodes over a 
4-week period when used as needed.34 The APO302 
study undertaken in 62 patients at 26 USA centres 
demonstrated that apomorphine injection was 
able to achieve rapid and reliable improvements in 
UPDRS motor scores compared with placebo.35 
These significant improvements in mean 
UPDRS motor scores were seen 20 mins after 
administration of apomorphine injection. In 
addition, apomorphine injection significantly and 
rapidly improved mobility as early as 7.5 mins after 
dosing, and this effect persisted for at least 40 mins 
after dosing. Apomorphine injection was found 
to be effective over the long term, with efficacy 
being maintained in patients with an average 
therapy duration of 14.5 months. The APO303 
study of 56 apomorphine-naïve patients with 
advanced PD at 17 USA centres provided further 
confirmationof the ability of apomorphine 
injection to provide rapid, effective relief of OFF 
episodes in PD patients already receiving 
optimised oral medication.36 Mean changes from 
pre-dose in UPDRS motor were significantly 
improved following apomorphine injection (4 mg) 
versus placebo at 20 mins (p=0.0002), 40 mins 
(p<0.0001; maximum improvement), and 90 mins 
(p=0.0229) post-administration.
Prof Isaacson described how the use of 
apomorphine pen injection (Figure 3) has been 
investigated in the recently completed Phase IV, 
10-centre, open-label, efficacy and safety study – 
AM-IMPAKT (Apokyn for Motor IMProvement of 
morning AKinesia Trial).37-39 AM-IMPAKT aimed to 
investigate whether subcutaneous apomorphine 
injection given upon awakening was able to provide 
rapid and reliable improvement in motor symptoms 
in PD patients with morning akinesia due to 
delayed onset of the first oral levodopa dose. During 
the 7-day baseline study period, each morning 
following their first oral levodopa dose, patients 
recorded their TTO in a diary every 5 mins for up 
to 60 mins by checking boxes either ‘yes’ or ‘no’ 
until onset of ON. Patients subsequently initiated 
treatment with the apomorphine pen and used this 
for another 7 days upon awakening, completing the 
same TTO diary each morning. The primary endpoint 
was a comparison of TTO between the levodopa 
study period and the apomorphine injection period. 
Morning akinesia was found to be common in the 
study population and occurred throughout the 
course of PD, even at relatively early stages. Over 
half of the PD patients who entered the study were 
in the first decade of their disease and, despite a 
range of oral therapies, had experienced persistent 
morning akinesia for an average of 4 years. 
The final analysis of data for 88 patients found that 
apomorphine pen injection significantly improved 
the primary endpoint of TTO: mean baseline 
TTO with levodopa averaged 60.64 mins, which 
reduced significantly to a mean of 23.95 mins with 
apomorphine injection (p<0.0001; Figure 4), 
representing a mean change from baseline of 
36.7 mins. UPDRS motor scores were also 
significantly reduced within 15 mins of apomorphine 
compared with baseline (35.5 versus 17.3; 
p<0.0001), representing a mean change in UPDRS 
score of 18.2.
Analysis of individual data for each patient was 
very revealing and demonstrated the reliability 
of the response to apomorphine injection. 
Approximately 98% of patients experienced a 
rapid and robust clinical improvement in TTO with 
apomorphine injection. Dose failures were found to 
be common during the levodopa baseline period; 
however, most of these patients achieved an ON 
state with apomorphine injection, the majority 
within 20 mins. 
Significant improvements were also found for the 
secondary patient-reported outcomes following 
treatment with apomorphine injection. Patients 
and investigators were asked to rate their global 
impression of severity of illness relative to akinesia/
motor function before and after apomorphine 
therapy, measured on a 7-point scale from 
‘normal’ to ‘extremely ill’. In both cases significant 
improvements were recorded (p<0.0001). Measures 
of health-related QoL also showed improvement 
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Prof Isaacson concluded by highlighting the 
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Summary
Prof Trenkwalder concluded the symposium by 
noting that an Expert Consensus Group Report 
on the use of subcutaneously administered 
apomorphine for the management of PD had just 
been accepted for publication in Parkinsonism 
& Related Disorders. The publication provided 
both a review of the published literature on 
the use of apomorphine and also consensus 
recommendations prepared by 26 advisors from 
13 countries to help guide healthcare professionals 
in the optimal application of apomorphine therapy 
in clinical practice.
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